[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO4770964A1 - Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos - Google Patents

Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos

Info

Publication number
CO4770964A1
CO4770964A1 CO96058504A CO96058504A CO4770964A1 CO 4770964 A1 CO4770964 A1 CO 4770964A1 CO 96058504 A CO96058504 A CO 96058504A CO 96058504 A CO96058504 A CO 96058504A CO 4770964 A1 CO4770964 A1 CO 4770964A1
Authority
CO
Colombia
Prior art keywords
preparation
compounds
procedure
amino acid
pharmaceutical compositions
Prior art date
Application number
CO96058504A
Other languages
English (en)
Inventor
Gerd Schnorrenber
Gunther Giesler
Birgit Jung
Georg Speck
Hans-Peter Ignatow
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of CO4770964A1 publication Critical patent/CO4770964A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS DERIVADOS DE AMI NOACIDOS DE LA FORMULA GENERAL I Y SUS SALES FARMA CEUTICAMENTE ACEPTABLES, EN DONDE R1,A1,A2,R2,R1 Y R11 POSEEN LOS SIGNIFICADOS INDICADOS EN LA MEMO RIA DESCRIPTIVA, ASI COMO SU PREPARACION Y EMPLEO. LOS NUEVOS COMPUESTOS SON VALIOSOS ANTAGONISTAS DE NEUROQUININA *TAQUININA
CO96058504A 1995-11-06 1996-11-06 Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos CO4770964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541283A DE19541283A1 (de) 1995-11-06 1995-11-06 Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
CO4770964A1 true CO4770964A1 (es) 1999-04-30

Family

ID=7776728

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96058504A CO4770964A1 (es) 1995-11-06 1996-11-06 Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos

Country Status (12)

Country Link
US (1) US6232468B1 (es)
EP (1) EP0871653B1 (es)
JP (1) JP3912798B2 (es)
AR (1) AR004291A1 (es)
AT (1) ATE235507T1 (es)
AU (1) AU7562296A (es)
CA (1) CA2234610C (es)
CO (1) CO4770964A1 (es)
DE (2) DE19541283A1 (es)
MX (1) MX9803004A (es)
WO (1) WO1997017362A1 (es)
ZA (1) ZA969248B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307809B1 (it) * 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
GB2418426A (en) * 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
EA019115B1 (ru) 2005-07-15 2014-01-30 Олбани Молекьюлар Рисерч, Инк. Арил- и гетероарилзамещенные тетрагидробензазепины и их применение для блокировки обратного захвата норэпинефрина, допамина и серотонина
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2336120B1 (en) 2007-01-10 2014-07-16 MSD Italia S.r.l. Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
BRPI1008008A2 (pt) * 2009-02-24 2016-02-23 Novartis Ag usos de antagonistas do receptor de nk
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
AU2010307198C9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CA2833009A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
GB9113219D0 (en) * 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
DK0610487T3 (da) * 1992-09-03 2000-05-15 Boehringer Ingelheim Pharma Nye aminosyrederivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
DE4243496A1 (de) * 1992-09-03 1994-03-10 Boehringer Ingelheim Kg Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4445939A1 (de) * 1994-05-07 1995-11-09 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen (II)
NZ285750A (en) 1994-05-07 1998-08-26 Boehringer Ingelheim Int Neurokinin (tachykinin) antagonists

Also Published As

Publication number Publication date
MX9803004A (es) 1998-09-30
JP3912798B2 (ja) 2007-05-09
EP0871653B1 (de) 2003-03-26
WO1997017362A1 (de) 1997-05-15
JP2000501382A (ja) 2000-02-08
ATE235507T1 (de) 2003-04-15
ZA969248B (en) 1997-05-06
AR004291A1 (es) 1998-11-04
AU7562296A (en) 1997-05-29
EP0871653A1 (de) 1998-10-21
DE59610280D1 (de) 2003-04-30
CA2234610C (en) 2007-04-24
DE19541283A1 (de) 1997-05-07
CA2234610A1 (en) 1997-05-15
US6232468B1 (en) 2001-05-15

Similar Documents

Publication Publication Date Title
CO4770964A1 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
PA8439101A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
UY27109A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
TR200001973T2 (tr) 11 ß-halojen-7alfa-ile ikame edilmiş-estratrienler, bu 11ß-halojen-7alfa-ile ikame edilmiş-estratrienleri içeren farmasötik terkiplerin üretimi için yöntem ve ilaç üretiminde kullanımları.
TR200001079T2 (tr) Bisiklik kinaz inhibitörleri.
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
HUP0002104A2 (hu) Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
PT824530E (pt) Derivados de arilglicinamida, processos para a sua producao e preparacoes farmaceuticas contendo estes compostos
AR015712A1 (es) Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
UY26513A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimiento para su preparación.
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
PA8486701A1 (es) Antagonistas de 5ht1 para terapia antidepresiva
BG106847A (en) Substituted piperazine derivatives as mtp inhibitors
FI964045A (fi) CCK:ta tai gastriinia säätelevä 5-heterosykli-1,5-bentsodiatsepiinejä
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
PE45195A1 (es) Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
PT1273572E (pt) Piperazinas substituidas com tiofeno uteis no tratamento da hiperplasia prostatica benigna